India to Myanmar: Amlodipine Export Trade Route

To import Amlodipine formulations into Myanmar, the following steps must be undertaken:

2. Importation Approval: Post-registration, an Importation Approval Certificate must be obtained from the FDA Myanmar before the actual importation of the product.

3. Fees and Timelines: While specific fees and approval timelines are not publicly detailed, applicants should anticipate administrative costs and a review period that may extend several months, depending on the completeness of the submission and the FDA's evaluation process.

4. GMP Inspection Requirements: The FDA Myanmar may require GMP inspections of the manufacturing facilities. Indian manufacturers must ensure their facilities comply with GMP standards recognized by Myanmar to facilitate the approval process.

Indian exporters of Amlodipine formulations must adhere to the following quality and GMP standards:

1. GMP Certification: Manufacturing facilities must possess a valid GMP certificate issued by the competent authority in India. This certificate should align with the standards recognized by the NDRA under the ASEAN MRA.

2. Approved Facilities: While a comprehensive list of Indian facilities approved by Myanmar's FDA is not publicly available, exporters should ensure their manufacturing sites meet the required GMP standards and are prepared for potential inspections by Myanmar authorities.

3. Regulatory Actions: As of March 2026, there have been no publicly reported regulatory actions by the NDRA against Indian pharmaceutical companies exporting to Myanmar. However, exporters should remain vigilant and comply with all regulatory requirements to avoid potential issues.

Several regulatory developments between 2024 and 2026 have implications for Indian pharmaceutical exports to Myanmar:

1. Revised Schedule M Compliance in India: In December 2023, India's Ministry of Health and Family Welfare introduced updated Schedule M requirements, enhancing GMP standards. Large manufacturers were required to comply by June 28, 2024, while small and medium enterprises (SMEs) were given until December 28, 2024. However, recognizing the challenges faced by SMEs, the government extended the compliance deadline to December 31, 2025. This extension allows Indian SMEs additional time to upgrade their facilities, ensuring continued eligibility to export to markets like Myanmar.

2. E-Submission System in Myanmar: In October 2025, Myanmar's FDA implemented an electronic submission system for drug registration applications. This system streamlines the registration process, allowing for more efficient submission and review of applications. Indian exporters must familiarize themselves with this system to ensure timely and accurate submissions.

3. Annual Fees and Laboratory Testing: As per the amendment to the Drug Registration Notification in October 2025, imported registered drugs are subject to annual fees payable via an online payment system. Additionally, these products must undergo laboratory testing once every five years, with the associated analysis fee also payable online. Non-compliance with these requirements may result in the non-renewal of the registration certificate.

Staying informed about these regulatory changes is crucial for Indian exporters to maintain compliance and ensure uninterrupted access to the Myanmar pharmaceutical market.

In 2024, Myanmar's market for amlodipine formulations was valued at approximately $15.7 million, with imports from India accounting for the entirety of this market. The demand for amlodipine is primarily driven by the prevalence of hypertension and cardiovascular diseases, which have been on the rise due to factors such as an aging population and increased urbanization. Healthcare spending in Myanmar has been increasing, with the government allocating more resources to improve access to essential medicines. As of 2024, Myanmar does not have significant domestic production of amlodipine formulations, relying heavily on imports to meet its needs.

Myanmar imposes a Most-Favored-Nation (MFN) import duty of 5% on pharmaceutical products classified under HS code 30049072. However, under the ASEAN Trade in Goods Agreement (ATIGA), imports from ASEAN member states, including India, benefit from a 0% import duty on pharmaceutical products. Additionally, pharmaceutical imports are subject to a commercial tax, which varies depending on the product category. As of 2024, there are no anti-dumping duties imposed on amlodipine formulations imported into Myanmar.

India is the predominant supplier of amlodipine formulations to Myanmar, accounting for nearly 100% of the imports in this category. Other countries have a minimal presence in the Myanmar market for amlodipine formulations. India's competitive pricing, coupled with the preferential tariff rates under ATIGA, positions it favorably against potential competitors from countries like China and the European Union. The average import price for amlodipine 5mg tablets in Myanmar was approximately $0.34 per tablet in 2024, reflecting India's cost-effective production capabilities.

India has solidified its position as a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. This dominance is underpinned by a vast network of over 750 US FDA-approved manufacturing facilities and more than 2,000 WHO-GMP-certified plants, the highest number outside the United States. Such extensive infrastructure ensures that Indian manufacturers can produce high-quality finished pharmaceutical formulations, including those containing Amlodipine, at competitive prices. The cost advantages stem from lower labor expenses, efficient production processes, and economies of scale. Notably, companies like Alembic Pharmaceuticals have received US FDA approvals for Amlodipine and Atorvastatin tablets as of May 2025, highlighting India's capability to meet stringent international regulatory standards.

When comparing the export of Amlodipine formulations, India offers a compelling balance of cost and quality. In Q1 2025, the price of Amlodipine Besylate in China was approximately $72,411 per metric ton, while in Germany, it was around $75,369 per metric ton. Indian manufacturers, benefiting from lower production costs, can offer competitive pricing without compromising quality. The perception of Indian pharmaceutical products is bolstered by the country's adherence to international regulatory standards, with numerous facilities approved by the US FDA and WHO-GMP. In contrast, while the EU offers high-quality branded generics, the costs are typically higher due to stringent regulatory requirements and higher production expenses. China, although a significant player in the API market, faces challenges related to quality perception and regulatory compliance in certain markets. For Myanmar, Indian Amlodipine formulations present an optimal mix of affordability, quality, and regulatory acceptance.

The India-Myanmar supply chain for Amlodipine formulations has demonstrated reliability, supported by India's substantial manufacturing capacity. Companies like Lupin have expanded their infrastructure, with 15 cGMP-compliant manufacturing facilities across three continents, including 11 US FDA-approved sites. These facilities adhere to stringent quality standards, ensuring consistent product quality. While there have been occasional global supply disruptions due to factors like environmental policies and raw material price fluctuations, Indian manufacturers have shown resilience by diversifying supply sources and investing in infrastructure. For instance, Lupin's expansion of manufacturing infrastructure across key sites indicates a proactive approach to meeting global demand. Overall, Indian manufacturers maintain a strong track record of regulatory compliance and supply reliability.

For Myanmar buyers aiming to source Amlodipine formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian suppliers to mitigate risks associated with supply disruptions and ensure consistent product availability.

• Minimum Order Quantities (MOQs): Indian manufacturers typically have flexible MOQs, but it's advisable to negotiate terms that align with your demand forecasts to optimize inventory levels.

• Payment Terms: Common payment terms in India-Myanmar pharmaceutical trade include Letters of Credit (LC) and Telegraphic Transfers (TT). Establish clear payment agreements to maintain smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence by reviewing potential suppliers' regulatory approvals (e.g., US FDA, WHO-GMP), manufacturing capabilities, and quality control measures. Site visits and audits can provide additional assurance.

• Regulatory Compliance: Ensure that the selected Indian suppliers comply with Myanmar's pharmaceutical import regulations, including product registration and labeling requirements, to facilitate seamless market entry.

By implementing these strategies, Myanmar buyers can establish a robust and reliable supply chain for Amlodipine formulations sourced from India.

By meticulously following these guidelines, Myanmar companies can ensure the selection of reliable Indian suppliers for Amlodipine formulations, thereby safeguarding product quality and patient safety.